Boston An independent LDT provider

CEO

Picture of Jeff Borcherding, CEO of Immunovia, Inc.

Jeff Borcherding

Jeff Borcherding joins Immunovia from Myriad Genetics, a leader in genetic testing and precision medicine, where he most recently served as Chief Marketing Officer. Previously, Jeff was the general manager for Myriad’s mental health business unit, leading dramatic growth of Myriad’s GeneSight test. Jeff is a former Procter & Gamble brand manager, where he successfully grew multiple healthcare brands. He has held several commercial leadership roles at health care and software companies. Jeff is a graduate of Indiana University with a B.S. in business and earned an MBA from the Kellogg Graduate School of Management at Northwestern University.

Medical director

Thomas C. King, MD, PhD

Dr. Thomas King is a board-certified pathologist with a PhD in molecular biology. He has extensive experience as a laboratory director in hospital, academic, and corporate settings.

Dr. King received his MD and PhD degrees from Washington University in 1984 through the NIH-funded Medical Scientist Training Program (MSTP). After completing residency in anatomic pathology at Washington University Medical Center in 1987, Dr. King moved on to become an Associate Professor of Pathology at Brown University, where he was also Pathology Residency Program Director and acting Chief of Pathology. He was subsequently Senior Director of Molecular Pathology at Millennium Pharmaceuticals and an Associate Professor at Boston University School of Medicine. Dr. King is currently the Medical Director of Immunovia, Inc., in Marlborough, Massachusetts, employing proteomic biomarkers as diagnostic tools.